Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: A Wisconsin Oncology Network study

Hematological Oncology

Volumn 27, Issue 1, 2009, Pages 11-16

  Chang, J E ^a   Voorhees, P M ^a,d   Kolesar, J M ^a   Ahuja, H G ^b   Sanchez, F A ^c   Rodriguez, G A ^c   Kim, K ^a   Wemdli, J ^a   Bailey, H H ^a   Kahl, B S ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b Aspirus Cancer Center   (United States)

^c Oncology Associates   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Arsenic trioxide; Ascorbic acid; Lymphoma

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; GLUTATHIONE; PROTEIN BAX; PROTEIN BCL 2; ORGANOARSENIC DERIVATIVE; OXIDE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE EXPRESSION; GLUTATHIONE METABOLISM; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPOXIA; INFECTION; LEUKOPENIA; LYMPHOMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QT PROLONGATION; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CHRONIC LYMPHATIC LEUKEMIA; LEUKEMIA; METABOLISM; MIDDLE AGED; NONHODGKIN LYMPHOMA; SAFETY;

ADULT; AGED; AGED, 80 AND OVER; ARSENICALS; ASCORBIC ACID; FEMALE; GLUTATHIONE; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; OXIDES; SAFETY;

EID: 65249172078     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.870     Document Type: Article

References (45)

1. Zhang P, Wang SY, Hu XH. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996; 17: 58-72.
2. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide in the treatment of acute promyelocytic leukemia (APL): clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
3. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-3324.
4. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.
5. Schiller GJ, Slack J, Hainsworth JD, et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 2006; 24: 2456-2464.
6. Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 2006; 24: 2465-2471.
7. Dutcher JP, Wiernik PH, Garl S. Major hematologic response in a patient with myelodysplasia to arsenic trioxide. Blood 2000; 96: 260b.
8. Munshi NC, Tricot G, Desikan R, et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002; 16: 1835-1837.
9. Munshi NC. Arsenic trioxide: an emerging therapy for multiple myeloma. Oncologist 2001; 6 (Suppl 2): 17-21.
10. 3) in high risk refractory multiple myeloma. Blood 1999; 94 (Suppl 1): 123a.
11. Hussein MA, Saleh M, Ravandi F, et al. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 2004; 125: 470-476.
12. Zhang W, Ohnishi K, Shigeno K, et al. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998; 12: 1383-1391.
13. Zhu XH, Shen YL, Jing YK, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999; 91: 772-778.
14. König A, Wrazel L, Warrell RP, et al. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997; 90: 562-570.
15. Akao Y, Mizoguchi H, Kojima S, et al. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of capsases and down-regulation of Bcl-2 protein. Br J Haematol 1998; 102: 1055-1062.
16. Ranvandi F, van Besien K. Clinical activity of arsenic trioxide in Burkitt-like lymphoma. Leukemia 2003; 17: 271-272.
17. 3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-3353.
18. Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development studies. Oncologist 2001; 6 (Suppl 2): 22-28.
19. Jing Y, Dai J, Chalmers-Redman R, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-2111.
20. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox systems. Blood 1999; 93: 268-277.
21. Yang CH, Kuo ML, Chen JC, Chen YC. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1999; 81: 796-799.
22. Grad JM, Bahlis NJ, Reis I, et al. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001; 98: 805-813.
23. Ramanathan K, Balakumar BS, Panneerselvam C. Effects of ascorbic acid and alpha-tocopherol on arsenic-induced oxidative stress. Hum Exp Toxicol 2002; 21: 675-680.
24. Ramanathan K, Shila S, Kumaran S, Panneerselvam C. Ascorbic acid and alpha-tocopherol as potent modulators on arsenic induced toxicity in mitochondria. J Nutr Biochem 2003; 14: 416-420.
25. Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukemia. Br J Haematol 2001; 112: 783-786.
26. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for nonHodgkin lymphomas: NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
27. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Groups guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
28. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 1969; 27: 502-522.
29. A predictive model for aggressive non-Hodgkin lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
30. 3) in the treatment of patients with acute promyelocytic leukemia: the M.D. Anderson experience. Cancer 2003; 97: 2218-2224.
31. Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107: 2627-2632.
32. Berenson JR, Boccia R, Siegel D, et al. Efficacy and safety of melphalan, arsenic trioxide, and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 2006; 135: 174-183.
33. Abou-Jawde RM, Reed J, Kelly M, et al. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol 2006; 23: 263-272.
34. L. Blood 2000; 95: 1014-1022.
35. 3 induces NB-4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996; 88: 1052-1061.
36. Lee C, Lin Y, Huang M, et al. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo. Leuk Lymphoma 2006; 47: 521-529.
37. Bailey HH, Mulcahy RT, Tutsch KD, et al. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J. Clin Oncol 1994; 12: 194-205.
38. L-S,R-buthionine sulfoximine with intravenous melphalan. J. Natl Cancer Inst 1997; 89: 1789-1796.
39. Meister A. Glutathione, ascorbate, and cellular protection. Cancer Res 1994; 54 (Suppl 7): 1969-1975.
40. Rojewski MT, Körper S, Schrezenmeier H. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. Leuk Lymphoma 2004; 45: 2387-2401.
41. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/ refractory multiple myeloma. Clin Cancer Res 2002; 8: 3658-3668.
42. Mathas S, Lietz A, Janz M, et al. Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis. Blood 2003; 102: 1028-1034.
43. Kim KB, Bedikian AY, Camacho LH, Papadopoulos NE, McCullough C. A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer 2005; 104: 1687-1692.
44. Beer TM, Tangen CM, Nichols CR, et al. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer 2006; 106: 2624-2629.
45. Litzow MR, Lee S, Bennett JM, et al. A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. Haematologica 2006; 91: 1105-1108.